What are myeloproliferative neoplasms?
Myeloproliferative Neoplasms (MPNs) are a group of chronic blood cancers where the bone marrow produces too many blood cells. These abnormal cells can thicken the blood, affect blood flow, and lead to complications such as blood clots, bleeding, or enlargement of the spleen.
The main types of MPN include:
- Polycythaemia Vera (PV) — too many red blood cells.
- Essential Thrombocythaemia (ET) — too many platelets.
- Myelofibrosis (MF) — scarring of the bone marrow.
- Chronic Myeloid Leukaemia (CML) — abnormal white blood cells caused by the BCR-ABL1 gene.
MPNs are usually long-term conditions and can vary in severity. Many patients can live normal lives with monitoring and treatment.
What are the signs & symptoms of myeloproliferative neoplasms?
Symptoms may vary by MPN subtype but commonly include:
- Fatigue or weakness
- Headaches, dizziness, or blurred vision
- Easy bruising or bleeding
- Night sweats
- Unexplained weight loss
- Itching, especially after a warm shower (common in PV)
- Tingling or burning in the hands or feet
- Fullness or discomfort on the left side due to an enlarged spleen
- Bone pain
- Shortness of breath
- Blood clots (stroke, deep vein thrombosis, heart attack)
A doctor should be consulted if the above symptoms occur.
What are the risk factors of myeloproliferative neoplasms?
- Age: Most patients are above 50 years old.
- Genetic mutations: such as JAK2, CALR, MPL, and BCR-ABL1.
- Family history of blood cancers.
- Previous cancer treatments such as chemotherapy.
How are myeloproliferative neoplasms diagnosed?
Diagnosis typically includes a combination of the following:
Blood Tests
- Full blood count (FBC) — looks for elevated or low red cells, white cells, or platelets.
- Blood film — examines cell shape and maturity.
- Erythropoietin (EPO) and iron level testing.
Genetic and Molecular Testing
Detects mutations such as JAK2 V617F, CALR, MPL, and BCR-ABL1.
Bone Marrow Biopsy
Examines the bone marrow structure, checks cell production, and assesses for fibrosis (scarring).
Imaging
Ultrasound or CT scan to determine spleen size.
What are the treatment options for myeloproliferative neoplasms?
Common Treatments
- Phlebotomy (for PV) — regular removal of blood to reduce red cell levels.
- Cytoreductive Therapy — includes Hydroxyurea, Pegylated interferons, Anagrelide, and Busulfan (less common).
- Targeted Therapy
- JAK inhibitors (e.g., Ruxolitinib, Fedratinib, Momelotinib) for MF or hydroxyurea-resistant PV.
- Tyrosine kinase inhibitors (TKI) for CML (e.g., Imatinib, Dasatinib, Nilotinib).
- Low-dose Aspirin — reduces the risk of blood clots.
- Blood Transfusion — for management of anaemia.
- Supporting Agents for Anaemia — such as Danazol and Erythropoiesis Stimulating Agents.
- Stem Cell Transplant — for selected cases of Myelofibrosis.
Supportive Care
- Management of itching, bone pain, or constitutional symptoms.
- Treatment of complications such as blood clots or spleen enlargement.
Living with myeloproliferative neoplasms
Living with MPN is often a long-term journey. Support, monitoring, and lifestyle adjustments can help patients stay well.
Support resources and programmes available include psychosocial and emotional support, nutritional counselling, patient support groups (PSG), and Patient Wellness Programme (PWP) activities such as exercise, mindfulness, and rehabilitation.